New Oral Drug Cuts Multiple Myeloma Progression Risk by 52% in Phase III Trial
Mezigdomide triplet nearly doubled progression-free survival to 18 months in relapsed myeloma patients refractory to standard therapies.
Summary
A phase III clinical trial called SUCCESSOR-2 found that adding the oral drug mezigdomide to a standard multiple myeloma treatment regimen nearly doubled how long patients lived without their cancer worsening. In patients whose myeloma had stopped responding to common treatments like lenalidomide and anti-CD38 antibodies, the mezigdomide combination extended median progression-free survival from 8.3 months to 18 months — a 52% reduction in the risk of disease progression or death. Presented at the 2026 ASCO annual meeting, this is the first phase III result for a CELMoD drug, a newer class that works more powerfully than older immunomodulatory drugs. Researchers say the oral, community-friendly regimen could become a new standard of care for this difficult-to-treat population.
Detailed Summary
Multiple myeloma is a blood cancer that becomes increasingly hard to treat as patients cycle through available therapies. A significant number of patients today are exposed upfront to quadruplet regimens, leaving them resistant to lenalidomide and anti-CD38 antibodies when they relapse — a situation that severely limits treatment options. The SUCCESSOR-2 trial directly addresses this growing clinical problem with a novel therapeutic class.
The phase III trial found that adding mezigdomide — a cereblon E3 ligase modulator, or CELMoD drug — to the standard carfilzomib and dexamethasone regimen produced a median progression-free survival of 18 months, compared with just 8.3 months for the two-drug control arm. This translates to a hazard ratio of 0.48, meaning a 52% reduction in the risk of disease progression or death. Results were highly statistically significant.
Mezigdomide works by binding cereblon more effectively than older drugs like lenalidomide or pomalidomide, enhancing myeloma cell killing and immune stimulation. Crucially, it can override resistance mechanisms to existing immunomodulatory drugs, making it relevant even for heavily pretreated patients. It previously demonstrated a 50% response rate in patients already exposed to CAR-T or bispecific therapies.
The second progression-free survival — tracking outcomes after a subsequent line of therapy — also favored the triplet arm at 23.6 versus 13 months. Discussants noted this benefit was achieved even though the control arm had greater access to novel salvage therapies including CAR-T and bispecifics. The oral delivery and manageable safety profile make it viable across community oncology settings.
One important caveat is that overall survival data are not yet mature. Additionally, a related CELMoD drug, iberdomide, is currently under FDA review. Both drugs represent an emerging class with real promise, but long-term durability and comparative data against newer cellular therapies remain to be established.
Key Findings
- Mezigdomide triplet cut risk of myeloma progression or death by 52% vs standard two-drug regimen.
- Median progression-free survival nearly doubled from 8.3 months to 18 months in refractory patients.
- Second progression-free survival also improved: 23.6 vs 13 months, despite control arm accessing more novel therapies.
- Mezigdomide showed 50% response rate in patients previously treated with CAR-T or bispecific agents.
- Oral delivery and community-practice compatibility make this regimen broadly accessible if approved.
Methodology
This is a news report from MedPage Today covering a late-breaking phase III clinical trial (SUCCESSOR-2) presented at ASCO 2026. The trial includes a comparator arm and reports hazard ratios with confidence intervals, indicating robust randomized controlled trial methodology. MedPage Today is a credible, peer-reviewed-adjacent medical news outlet; primary data have not yet been published in a peer-reviewed journal.
Study Limitations
Overall survival data are not yet mature, so long-term survival benefit remains unconfirmed. The article is a conference report, not a peer-reviewed publication, so full trial data including adverse event details require independent verification. Generalizability may be limited by specific eligibility criteria not fully described in the article.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.